By Topic

Novel Controlled Attenuation Parameter for the evaluation of fatty liver disease

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

3 Author(s)
Sasso, M. ; R&D Dept., Echosens, Paris, France ; Miette, V. ; Sandrin, L.

There is a need for novel non-invasive methods to detect and quantify steatosis which is an intracellular accumulation of fat in the liver that can be associated in many cases with hepatitis. A novel attenuation parameter named Controlled Attenuation Parameter (CAP) has been developed to process the raw ultrasonic signals acquired by the Fibroscan® which is an ultrasound-based VCTE¿ device used to diagnose liver disease. Performance of the CAP parameter to detect and quantify steatosis is assessed in a large multi-etiology cohort of 495 patients, taking the histologic staging of steatosis as a reference. CAP is found to be significantly correlated to steatosis and its values are significantly different in each steatosis stages. Diagnosis performances were assessed using the ROC curves. Areas under ROC curves were found to be equal to 0.85 and 0.90 for the diagnosis of more than 10% and 33% of fatty deposit, respectively. Results obtained in this first preliminary study are very promising. Combination of both CAP and liver stiffness measurement may improve liver diseases diagnosis performance.

Published in:

Ultrasonics Symposium (IUS), 2009 IEEE International

Date of Conference:

20-23 Sept. 2009